The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of ... MarketWatch (press release) Today Biogen Idec (NASDAQ:BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase 2b study designed to determine the efficacy ... |
